:format(webp))
However, these groundbreaking medical innovations require a monumental shift in how global supply chains operate. Moving living, highly perishable biological materials across borders with zero margin for error demands an entirely new logistical playbook.
In this video, Michael Sweeney, QuickSTAT’s Global Head of Strategy for CGT & DTP, shares expert perspectives on navigating the frontiers of advanced therapeutics.
Learn why the global logistics ecosystem must rapidly evolve to match the speed of medical innovation, and how early strategic planning can secure the pathway from clinical success to commercial reality.
How QuickSTAT synchronizes the entire chain of custody, from the initial collection of a patient's cells at a clinical site to manufacturing and back to the hospital for infusion.
The critical steps required to transition a highly sensitive supply chain from small-scale clinical trial phases to robust, high-volume commercial distribution.
A look at the advanced cold chain solutions and ultra-fast routing strategies used to preserve the viability of living cells that must remain frozen at cryogenic temperatures.
How specialized logistics teams map out alternative lanes and build redundancies into shipping plans to completely bypass customs delays or transit disruptions.
Loading iFrame
Press play to get started.
Direct impact on patient lives: Because advanced therapies are often autologous (created specifically using a patient's own cells), a single logistical failure means a patient may lose their only chance at treatment.
Protecting the integrity of innovation: Years of research and significant financial investments rely entirely on the final transport phase. Flawless execution ensures that the medicine arriving at the bedside matches the exact quality of the laboratory.
Embedding logistics early prevents failure: Integrating supply chain design into early-stage clinical trial development allows developers to identify and eliminate vulnerabilities before scaling globally.